TC BioPharm (Holdings) plc: Nasdaq/NYSE listing notice — TC BioPharm regains Nasdaq minimum bid price compliance, avoids delisting

TC BioPharm (Holdings) plc

Received Nasdaq confirmation on Jan 2, 2024, that bid price exceeded $1.00 for 10 consecutive days through Dec 29, 2023.
Had been out of compliance since June 22, 2023, and initial 180-day cure period expired Dec 19, 2023.
Company not eligible for second 180-day extension, but regained compliance before delisting became effective.
Press release issued Jan 4, 2024; matter is closed with Nasdaq.
Resolution removes overhang of potential transfer to OTC or other exchange.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TC BioPharm (Holdings) plc received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 2, 2024, the Company received written confirmation from Nasdaq that it has determined that for the last 10 consecutive business days, from December 15, 2023 to December 29, 2023, the closing bid price of the Company’s securities has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter is now closed.

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001493152-24-000587

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.